cannabinoid receptor agonists

Summary

Summary: Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS.

Top Publications

  1. HURST D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. 2011;168:1119 pubmed publisher
  2. Hoffman A, Lupica C. Synaptic targets of ?9-tetrahydrocannabinol in the central nervous system. Cold Spring Harb Perspect Med. 2013;3: pubmed publisher
    ..Here we examine the recent literature describing the effects of acute and repeated THC exposure on synaptic function in several brain regions and explore the importance of these neurobiological actions of THC in drug addiction. ..
  3. Fanarioti E, Mavrikaki M, Panagis G, Mitsacos A, Nomikos G, Giompres P. Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2. Int J Neuropsychopharmacol. 2014;18: pubmed publisher
  4. Hasenoehrl C, Storr M, Schicho R. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?. Expert Rev Gastroenterol Hepatol. 2017;11:329-337 pubmed publisher
    ..Synthetic cannabinoid receptor agonists are also termed cannabinoids, some of which, like dronabinol and nabilone, are already available with ..
  5. Grim T, Morales A, Thomas B, Wiley J, Endres G, Negus S, et al. Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model. J Pharmacol Exp Ther. 2017;362:210-218 pubmed publisher
    ..More generally, affinity estimation offers a powerful pharmacological approach to assess potential receptor heterogeneity subserving in vivo pharmacological effects of SCs. ..
  6. Li A, Carey L, Mackie K, Hohmann A. Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther. 2017;362:296-305 pubmed publisher
    ..The present results suggest that the antiallodynic efficacy of GW405833 is CB1-dependent but does not seem to involve engagement of the CB1 receptor's orthosteric site. ..
  7. Chia C, Carlson O, Liu D, González Mariscal I, Santa Cruz Calvo S, Egan J. Incretin secretion in humans is under the influence of cannabinoid receptors. Am J Physiol Endocrinol Metab. 2017;313:E359-E366 pubmed publisher
    ..CBRs exert tonic control over GIP secretion, which may have a homeostatic effect in suppressing GLP-1 secretion. This raises the possibility that gut hormones are influenced by endocannabinoids. ..
  8. Hua T, Vemuri K, Nikas S, Laprairie R, Wu Y, Qu L, et al. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. 2017;547:468-471 pubmed publisher
    ..These findings should inspire the design of chemically diverse ligands with distinct pharmacological properties. ..
  9. Huizenga M, Wicker E, Beck V, Forcelli P. Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats. Epilepsia. 2017;58:1593-1602 pubmed publisher

More Information

Publications12

  1. Shi Y, Duan Y, Ji Y, Wang Z, Wu Y, Gunosewoyo H, et al. Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis. J Med Chem. 2017;60:7067-7083 pubmed publisher
    ..Furthermore, 57 significantly alleviated the clinical symptoms and protected the murine central nervous system from immune damage in an experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. ..
  2. Feliú A, Bonilla Del Río I, Carrillo Salinas F, Hernández Torres G, Mestre L, Puente N, et al. 2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination. J Neurosci. 2017;37:8385-8398 pubmed publisher
    ..The increased 2-arachidonoylglycerol tone promotes remyelination in a model of progressive multiple sclerosis ameliorating motor dysfunction. ..
  3. Rivera J, Vance E, Rushton W, Arnold J. Novel Psychoactive Substances and Trends of Abuse. Crit Care Nurs Q. 2017;40:374-382 pubmed publisher